Organigram ($OGI): Can Sanity Growth Turn Accounting Profit into Cash?

01 Organigram’s investment question, scenarios and disconfirming evidence

What Would Falsify This Reading

Sustained operating cash generation after working capital would weaken the concern that reported earnings overstate financial progress. Clear evidence of comparable medical demand, fewer collection delays and inventories converting without margin erosion would support the acquisition thesis. Conversely, repeat negative cash conversion despite strong adjusted profit, an adverse change in credit availability, or further valuation and control problems would undermine it. These are observable conditions, not share-price targets or assigned probabilities. The June 30, 2026 statements and August 11, 2026 MD&A provide the starting definitions against which later reporting should be compared.

02 What Organigram now owns and how the business earns revenue

The useful way to map Organigram is by economic activity, rather than by the number of countries named in a presentation. The August 11, 2026 MD&A describes a Canadian branded cannabis business, international medical sales, the newly acquired Sanity platform and wholesale or other revenue. Canadian brands sell through regulated channels with excise and provincial distribution economics. International medical activity involves supply standards, import permissions, distributors and prescribers. Owning a distributor can improve access and control of the final sale, but also places more inventory, receivables and local execution inside the consolidated balance sheet.

For the quarter ended June 30, 2026, the MD&A reports C$61.817 million of recreational revenue, C$39.033 million of medical revenue and C$4.932 million of wholesale and other revenue, each after excise. The separate geographical breakdown is C$65.519 million in Canada, C$39.873 million in Europe and C$0.390 million elsewhere, in the financial statements. These are alternative descriptions of the same consolidated revenue. Adding medical revenue to European revenue would double-count overlapping activity, while equating all Canadian sales with recreational cannabis would erase medical and wholesale distinctions.

The acquisition also changes where a sale appears. The August 11, 2026 MD&A explains that shipments from Organigram to Sanity within the consolidated group are eliminated; consolidated revenue is recognized when the product is sold outside the group. That matters when comparing the export line with the period before Sanity was owned. A lower visible export figure need not mean that final European demand fell, and internal shipments are not additional to Sanity’s external revenue; combining them would overstate sales. The economics have moved through a different reporting perimeter.

In Canada, brand breadth creates a way to compete across products and price points, but it is not a guarantee of pricing power. The July 20, 2026 corporate update reported an estimated June national market share of 11.1%, using the company’s market-data methodology. That figure is a company estimate, not an audited national revenue share. It combines an industry data model with the company’s definitions and reporting coverage. It is useful as a demand signal only when its period and method stay visible.

The central business question is whether distribution, product innovation and production together improve the retained gross contribution per sale. Owning more of the chain can remove an external intermediary but cannot remove regulatory costs, slow-moving stock or collection risk. Evidence of a stronger platform would be sustained external demand, reliable supply quality and cash conversion across the enlarged group. A list of brands or countries provides coverage; it does not show those outcomes. The June 30, 2026 statements make that distinction measurable through revenue categories, margins and the balance sheet.

03 Growth after Sanity and the limits of comparisons

The quarter ended June 30, 2026 is the first reported quarter containing Sanity, but the acquired company is consolidated from April 15, not from the beginning of April. The interim statements explicitly report Sanity’s post-acquisition revenue contribution of C$38.359 million and net-income contribution of C$6.508 million from April 15 through June 30, 2026. Calling that a full consolidated quarter would overstate the reporting period. It is also different from the standalone full-quarter Sanity sales discussed by management in another currency.

Consolidated net revenue was C$105.782 million in the June 2026 quarter versus C$70.792 million in the June 2025 quarter, according to the financial statements; management describes that increase as 49% in the August 11, 2026 results release. The comparison includes an acquisition absent from the earlier period. It proves growth in the reported group, not that each existing business grew by that percentage. A sound organic comparison would require equivalent companies, currencies, selling channels and recognition periods, with internal sales consistently eliminated.

The August 11, 2026 MD&A separately reports Sanity’s approximately €25.5 million of standalone revenue for April through June 2026. That amount covers the whole calendar quarter and is in euros; the C$38.359 million post-acquisition contribution in the statements covers a shorter period and is in Canadian dollars. Neither can be substituted for the other, and a difference between them is not itself evidence of lost sales or an accounting error. Exchange rates, consolidation dates and eliminations need to be considered before using the figures in a growth bridge.

Sequential comparisons require the same care. For the quarter ended March 31, 2026, the August 11, 2026 MD&A reports C$59.794 million of net revenue and C$0.870 million of adjusted EBITDA; those amounts precede the Sanity closing. The jump in the June quarter reflects a larger company as well as operating changes. The useful comparison is not simply how far the new quarter exceeds the old one. It is how much incremental gross profit remains after additional overhead, integration spending and the working capital needed to support the new activity.

Over the nine months ended June 30, 2026, revenue after excise was C$229.114 million versus C$179.122 million in the corresponding prior period, in the financial statements. The longer period includes quarters with and without Sanity, so it smooths some seasonal variation while still mixing business perimeters. Future reports should gradually make the enlarged group easier to assess. Until then, reported growth, acquired growth and the company’s separate market estimates need distinct labels. None is a replacement for the cash generated by external customers.

04 Gross margins, operating profit and biological fair value

Cannabis accounting makes gross profit unusually sensitive to estimates before the product has reached a final customer. The June 30, 2026 financial statements value biological assets using assumptions about expected yields, selling prices, costs and completion. An increase in a crop’s estimated value can enter reported profit before the product is sold. When harvested inventory is later sold, the earlier fair-value uplift is reflected in cost of sales. This accounting recognizes value across the production cycle; it does not mean that the company has collected cash at the valuation date.

For the quarter ended June 30, 2026, gross profit before fair-value adjustments was C$38.802 million, compared with C$22.423 million a year earlier, in the financial statements. The August 11, 2026 MD&A reports the corresponding margins as 37% and 32%. That measure is useful because it separates the sale-and-cost relationship from the biological valuation movements. It still depends on the cost base, provisions and the acquisition mix, so it is not an organic margin measure for an unchanged company.

The same quarter’s IFRS gross profit was C$41.422 million after a C$14.410 million realized fair-value adjustment on inventory and a C$17.030 million unrealized biological-asset gain, according to the statements. The signs matter: the inventory adjustment reduces the period’s gross profit while the biological gain increases it. Looking only at the final gross-profit line hides those movements. Neither should be reclassified as a new cash receipt from medical sales.

Management’s adjusted gross profit was C$39.065 million, or 37% of net revenue, in the June 2026 quarter, versus C$24.226 million, or 34%, a year earlier, according to the August 11, 2026 MD&A. It is a company-defined non-IFRS measure with a reconciliation. Its closeness to gross profit before fair value in this quarter does not make the definitions identical. Inventory provisions and other adjustments can change the relationship in later periods, so the company’s reconciliation remains essential to interpreting it.

Operating expenses reached C$36.092 million for the quarter ended June 30, 2026, compared with C$28.251 million in the prior-year quarter, leaving C$5.330 million of IFRS operating income versus a C$2.105 million operating loss, in the statements. This is meaningful operating improvement, but additional acquired overhead and continuing research are real economic costs. The constructive test is whether higher gross contribution consistently exceeds those costs without depending on favorable crop valuations. The adverse test is whether off-spec product, returns, discounts or overhead growth absorb the improved sales mix.

05 Why the reported profit is not the cash result

The June 30, 2026 interim statements report C$105.538 million of quarterly net income, while the same period generated C$5.330 million of operating income. The largest bridge is a C$105.783 million gain from remeasuring the preferred-share liability. This is a financing valuation movement, not revenue, a cash investment by BAT in that quarter, or profit earned by selling cannabis. A headline earnings multiple based on this quarter would therefore largely capitalize a non-recurring valuation event rather than a demonstrated recurring earnings stream.

The preferred instrument contains conversion and accretion terms that make its accounting value depend on financial assumptions. The June 30, 2026 statements explain that the estimated period of accretion changed, affecting the liability’s fair value. The accounting gain reflects the updated valuation of that instrument. It does not erase the instrument, eliminate its potential conversion into common shares or supply cash for suppliers. A later remeasurement could move reported earnings in the opposite direction without an equivalent immediate cash payment.

For the quarter ended June 30, 2026, management reported C$13.413 million of adjusted EBITDA versus C$5.694 million in the prior-year quarter in the August 11, 2026 MD&A. The measure excludes specified items, including research and development net of depreciation under the company’s definition. That makes it useful for management’s operating comparison, but it does not show all ongoing economic spending. Research remains a use of resources even when it is excluded from adjusted EBITDA, and interest, working capital and capital spending remain outside that headline.

The cash-flow statement supplies the next bridge. For the quarter ended June 30, 2026, operating cash flow before working-capital changes was positive C$6.168 million, but operating cash flow after those changes was negative C$4.297 million, in the MD&A. The difference shows cash tied up in the operating cycle. The business did generate some underlying cash, but the pre-working-capital amount is not cash available to distribute. Both statements omit part of the complete picture.

Over the nine months ended June 30, 2026, the financial statements report C$124.586 million of net income but a C$13.681 million operating loss. The August 11, 2026 MD&A reports C$27.070 million of operating cash outflow over those months. This longer view confirms that the quarterly earnings headline does not describe the group’s funding experience. The relevant improvement would be recurring operating profit that survives valuation reversals and converts into cash after the actual operating cycle. The latest accounts show progress on the operating line and an unresolved cash conversion problem.

06 Liquidity, credit facilities and the financing bridge

The most immediately spendable balance is smaller than the company’s total liquidity measure. At June 30, 2026, cash was C$10.851 million and short-term investments were C$0.816 million, with no restricted cash, according to the financial statements. The August 11, 2026 MD&A combines those balances as C$11.667 million, compared with C$84.420 million of cash, restricted cash and short-term investments at September 30, 2025. Those dates straddle the acquisition and related financing; the decline is not a measure of recurring operating burn alone.

At June 30, 2026, Organigram reported total liquidity of approximately C$49.1 million including C$37.432 million of undrawn facilities, in the MD&A. Undrawn capacity is access to borrowing under an agreement, rather than money already held without repayment obligations. Treating the whole total as cash would overstate financial independence. Treating the cash balance alone as the only resource would omit real committed credit access, subject to its terms and continued covenant compliance.

The April 15, 2026 closing announcement describes C$60 million of facilities, comprising a C$20 million term loan, a C$30 million revolver and a C$10 million operating line. At June 30, 2026, principal outstanding was C$20 million on the term loan and C$2.568 million on the operating line, with the revolver undrawn, according to the statements. The C$20.973 million carrying value of total borrowings is lower than the principal total because of unamortized financing costs. That accounting difference is not a reduction in the contractual principal owed.

The June 30, 2026 statements disclose secured borrowing, a net funded-debt-to-EBITDA covenant below 3 and a fixed-charge coverage covenant of at least 1.25, with compliance at the reporting date. The facilities mature in April 2029 under the closing announcement and financial statements. Covenants make future operating cash and lender definitions important: favorable accounting revaluation gains do not automatically create headroom under a credit agreement. Reported compliance is a dated fact, not a guarantee for subsequent quarters.

The nine-month cash-flow statement includes C$125.024 million of acquisition cash outflow net of acquired cash and C$84.222 million of financing inflow for the period ended June 30, 2026, in the financial statements. These transaction flows explain why the balance-sheet change cannot be annualized as a simple runway formula. Management must fund the operating cycle, integration, debt service and future acquisition consideration from a combination of available resources and business cash generation. A liquidity judgment therefore needs both the balance and the obligations attached to it.

07 Inventory and receivables determine cash conversion

Working capital is a financing mechanism as well as a balance-sheet label. At June 30, 2026, Organigram reported C$172.805 million of working capital in the August 11, 2026 MD&A. That figure includes assets that need to be sold or collected before they can pay a supplier. A positive working-capital balance therefore does not prove that the company holds equivalent cash. The acquisition enlarges the network in which products move and invoices are collected, increasing the importance of stock quality and payment timing.

Inventories were C$147.764 million at June 30, 2026 versus C$106.023 million at September 30, 2025, in the financial statements. The June balance consists of C$113.620 million of capitalized costs and C$34.144 million of fair-value adjustments in the same statements. The entire inventory balance is neither cash spent during the latest quarter nor cash waiting to be collected at face value. It includes production costs, acquisition effects and valuation components; eventual recovery depends on quality, demand, price and the expenses of completing and selling the products.

Accounts and other receivables were C$88.605 million at June 30, 2026 versus C$64.859 million at September 30, 2025, according to the statements. Gross trade receivables were C$90.375 million, net trade receivables C$86.742 million and the gross amount more than ninety days old C$14.992 million at June 30, 2026, in the same source. An aging balance is not proof that all of those invoices will be lost, but it identifies where cash conversion depends on collection rather than on new sales growth.

The quarter ended June 30, 2026 included a C$3.012 million recovery of a bad-debt provision, according to the quarterly general-and-administrative discussion in the MD&A. That supports the reported expense result but is not equivalent to a recurring improvement in product gross margin. Provisions, recoveries and cash receipts have different timing. A reader should ask whether subsequent accounts show actual collections, improved aging and lower disputes, rather than infer a permanent earnings benefit from one favorable provision movement.

For the nine months ended June 30, 2026, operating cash before working-capital changes was C$0.210 million, while changes in operating assets and liabilities absorbed C$12.381 million and C$14.899 million respectively, in the August 11, 2026 MD&A. The company’s free cash flow was negative C$28.965 million after C$1.895 million of property, plant and equipment spending, in the same source. Those figures locate the funding problem more precisely than the net-income line. Better evidence would be inventory selling through without major discounts and receivables becoming cash while new sales remain healthy.

08 Sanity’s fixed earnout and what integration can change

The April 15, 2026 closing announcement recorded upfront consideration of €107.3 million, comprising €78 million of cash and €29.3 million in share consideration comprising common and preferred shares, subject to closing adjustments. Those transaction amounts retain their euro denomination. The acquisition accounting in the June 30, 2026 financial statements translates and allocates consideration under IFRS; it is not another cash payment on top of the closing terms. The company acquired an operating platform and also accepted obligations attached to that purchase.

The original earnout depended on future performance and initially encouraged a period of separate Sanity operation. The August 20, 2026 announcement says the parties replaced it with a fixed amount equal to 85% of the original maximum, permitting earlier integration. The announcement describes €20 million of cash and approximately €76 million in shares, with the share portion subject to deductions including Organigram’s pre-acquisition interest. The August 31, 2026 material change report, filed September 1, provides further transaction and governance detail. These are amended terms, not an additional independent acquisition price to add blindly to the original maximum earnout.

The August 20 announcement specifies payment on April 1, 2027, with the cash payment and share issuance no later than May 1, 2027, subject to the agreement’s conditions. The share conversion price is based on a twenty-day TSX volume-weighted average price measured as of three days before payment, with a C$3.00 floor and C$4.00 cap under that announcement. Fixing the euro value removes a performance contingency; it does not fix the eventual number of common shares. The reference price, currency conversion and contractual deductions still matter.

At June 30, 2026, the acquisition-related contingent consideration liability was C$80.279 million in the financial statements. That balance predates the August amendment and is not the current accounting value of the fixed earnout. Later company reporting will need to show how the changed contractual obligation maps onto its revised accounting measurement. Keeping the reporting date visible prevents a stale contingent-liability number from being presented as if the amendment were already incorporated in those accounts.

Operationally, earlier integration can coordinate sourcing, inventory, product launches and management responsibilities. The August 20, 2026 announcement appointed Finn Age Hänsel to lead the rest-of-world business and serve as chief strategy officer, and Adrian Frenzel as global chief operating officer. Appointments and permission to integrate are concrete actions. Cost savings, faster collections and stronger margins are future outcomes that need evidence. On October 15, 2026 Organigram quantified the expected savings at C$8 million to C$10 million a year on a run-rate basis, with C$2 million of one-time costs in fiscal 2027, and said it will discontinue three brands while concentrating on SHRED, BOXHOT and Big Bag O’ Buds. Source The amended payment can be commercially sensible while still placing a cash claim and further common-share issuance ahead of investors.

09 BAT’s preferred shares, ownership and related-party governance

BAT’s financing relationship is a source of capital and strategic alignment, but its instruments need separate treatment from ordinary shares. The April 15, 2026 closing announcement reports completion of a C$65.2 million BAT private placement tied to the acquisition and the final deployment of the Jupiter investment pool. That pool should not still be advertised as an untouched reserve after the transaction. The proceeds helped fund a completed expansion; they are not a perpetual additional source of cash waiting outside the reported balance sheet.

The preferred shares are non-voting and convertible subject to an ownership threshold, as described in the April 15 announcement. The initial conversion relationship is one common share per preferred share, with 7.5% annual accretion until the contractual beneficial-ownership condition is met. The announcement describes the 30% common-share holding threshold and the 49% beneficial-ownership condition for ending accretion. Accretion is not an ordinary cash dividend, and the liability’s fair-value gain does not make future conversion irrelevant. The instrument affects earnings measurement and potential ownership in different ways.

At June 30, 2026, Organigram had 140,975,357 common shares and 49,204,022 preferred shares outstanding, with 51,823,554 potential common shares on conversion of the preferred instrument including accretion, according to the financial statements and the capital table in the MD&A. These counts are not interchangeable. Adding the original preferred-share count to a basic common count gives neither the reported basic count nor a complete fully diluted count. The fixed earnout and employee awards create other potential issuance pathways, while exercise conditions and conversion restrictions determine what becomes actual common equity.

The August 11, 2026 MD&A lists 141,006,497 common shares outstanding as of August 7, 2026 and discusses BAT’s approximately 48% effective ownership at June 30, 2026. That effective measure incorporates conversion economics; it is not a claim that BAT already casts that percentage of ordinary votes. Similarly, the September 30, 2026 Finviz data report ownership figures for their own perimeter. Those data fields do not override the issuer’s dated description of a complex preferred instrument.

The August 31, 2026 material change report describes related-party aspects of the earnout amendment, committee review, declared interests and abstentions. It also explains the applicable exemptions from formal valuation and minority approval under the transaction-size tests. An exemption means the specified legal condition for that procedure was met; it does not show that conflicts cannot exist. For minority common shareholders, the useful questions are how obligations were priced, who participated in decisions and how future issuance affects their economic share of the business.

10 Product innovation, Australia and the boundary of company claims

Organigram’s product portfolio supports more than an abstract cannabis-demand thesis. The March 5, 2026 SHRED Shotz announcement introduced a small-format beverage using the company’s FAST nanoemulsion approach, describing a 65 milliliter product with 10 milligrams of THC. Those are product specifications from a dated issuer announcement, not consumption advice. The company’s claimed onset relates to a defined pharmacokinetic measurement; it is not a promise that every consumer experiences the same effect or a clinical demonstration of superiority for a medical condition.

The March 5 announcement refers to a preliminary pharmacokinetic study and describes faster onset and a higher peak concentration under its stated comparison. A study of blood concentrations answers a different question from long-term safety, therapeutic efficacy or commercial repeat purchase. Patent-pending language also differs from a granted patent with enforceable claims. The commercially relevant follow-through is whether the product reaches authorized channels, keeps consistent quality, attracts repeat demand and contributes margin after development and marketing spending.

Brand strength can support that process, but market retail sales are not issuer revenue. The March 5, 2026 announcement cites more than C$200 million of SHRED retail sales during 2025 using the company’s market-data approach. Retail prices contain the economics of distribution, tax and sellers outside Organigram. Comparing that total directly with net revenue in the IFRS accounts would mix perimeters. Brand penetration is useful context for demand; the accounts remain the source for the amount the issuer actually recognizes.

International product expansion adds a second route. The February 24, 2026 Australian launch announcement described Edison and BOXHOT products through Leafio and Montu, including access to a distribution network covering more than four thousand pharmacies. Network reach is potential channel access, not proof that every pharmacy stocks a product or that prescriptions are guaranteed. The August 11, 2026 MD&A subsequently described commercial availability and the start of prescription sales during the June quarter, which moves the evidence beyond the initial launch announcement without proving future scale.

Innovation and distribution need to be judged together with production constraints. The August 11, 2026 MD&A discusses international flower quality issues and remediation, and uncertainty over EU-GMP certification timing at Moncton after major findings in the certification audit; additional documentation was submitted to the regulator in April 2026. A product or export opportunity can be attractive while qualification and consistent supply remain unfinished work. Certification, pharmacy reach and scientific claims each have their own evidentiary threshold. Treating an announced initiative as completed commercial execution would bypass the risks that determine whether the opportunity turns into sustainable revenue.

11 US hemp exposure and the current regulatory distinction

Organigram’s August 11, 2026 MD&A describes pausing or winding down its US hemp-derived THC activity and records an impairment associated with the Collective Project brand in the quarter ended March 31, 2026. The C$5.8 million impairment reported in that source is an accounting charge from that earlier quarter, not a new cash payment in June. The company’s US medical-entry possibilities remained under consideration in the August disclosure; they were not an already licensed and launched replacement platform.

The legal timetable has changed since that disclosure. Section 781 of Public Law 119-37, enacted November 12, 2025, originally made the revised federal hemp definition effective after a year. Section 2019 of Public Law 119-103, enacted September 2, 2026, limits application of those amendments until December 11, 2026 to the specified intermediate and final products containing cannabinoids that cannabis plants cannot naturally produce. The extension is selective. It is neither a repeal of the reform nor a statement that every hemp-derived intoxicating product is unrestricted under every other applicable law.

This distinction matters because a dated issuer explanation can remain an accurate account of its business decision while its legal context changes. The August decision to pause is a disclosed company action. The September statute is a later legal event. Neither establishes that Organigram subsequently restarted US sales, restored the impaired brand’s value or secured a medical-market authorization. A temporary legal change can alter available options without automatically changing the company’s reported operating perimeter.

Federal marijuana rescheduling is a separate question from the hemp definition, Canadian recreational sales or German medical distribution. It is not evidence that Organigram’s products can immediately move into US channels. Import permissions, federal and state product rules, licensing and the company’s own commercial decisions still matter. The August 11, 2026 MD&A identifies US entry as uncertain rather than a booked earnings stream. Any future US expansion therefore remains an option that would require specific new evidence.

For the financial reading, the stronger evidence is already visible in the Canadian and European business. The June 30, 2026 statements report the revenue and cash from the existing consolidated perimeter; a regulatory narrative cannot replace them. A future US opportunity would become material when the company discloses a legal route, concrete commercial commitments, funding and actual results. Until then, the company action, later legal amendment and possible future strategy are separate matters, and a sector headline alone does not justify higher present earnings expectations.

12 Acquisition accounting, controls and the next evidence to watch

The balance sheet now carries substantial acquired assets whose value depends on future performance. At June 30, 2026, goodwill was C$194.717 million and intangible assets C$203.506 million, compared with C$52.524 million and C$48.511 million respectively at September 30, 2025, in the financial statements. The provisional Sanity allocation included C$142.193 million of goodwill and C$171.070 million of intangible assets in that source. These are accounting representations of acquired future benefits, not a cash reserve available to fund the earnout or pay down borrowing.

The assets can be commercially valuable, but their recoverability depends on assumptions about growth, margins and the acquired platform. A later impairment would affect reported earnings and book equity without necessarily creating a cash payment in that period. Conversely, the absence of an impairment does not prove that the purchase generated an adequate return. Cash generation, customer retention and operating integration provide the economic evidence, while the accounting tests provide a separate check on the carrying values.

Other investments show why that distinction matters. At June 30, 2026, other financial assets included C$14.962 million for Phylos and C$4.869 million for Weekend, while the OBX investment had been written down to zero, according to the statements. Portfolio and innovation investments can offer technology or market access, but their carrying amounts are not immediately liquid resources. The loss of value in one investment does not prove that another will fail; it demonstrates that optionality and recoverable cash are different categories.

The August 11, 2026 MD&A reports that disclosure controls and internal control over financial reporting were ineffective at June 30, 2026 because of a material weakness involving complex spreadsheets used in biological-asset and inventory valuation. It describes remediation work and an expectation of completion by fiscal year end. The passage of September 30 does not prove that testing has subsequently established effective controls. The acquired Sanity business was excluded from that evaluation under the permitted acquisition scope exception, creating additional integration and reporting work rather than certifying its systems through the parent assessment.

Management’s August 11, 2026 outlook called for fiscal 2026 net revenue above C$350 million, stronger adjusted operating measures and modestly negative annual free cash flow. Those are forecasts issued before the fiscal year closed, not the completed year’s reported results. The next reports will need to show how the cash outcome, acquired growth, working capital, fixed consideration and control remediation fit together. The September 30, 2026 Investor Session release described the programme for the event held that day; a strategy event is not a substitute for the audited annual accounts or a new set of completed-quarter financial statements.

13 October 2, 2026 — developments and next dates

The September 30 Investor Session has taken place. Organigram’s subsequent company message thanked participants and said the full replay would be made available in the following days. The published programme assigned corporate strategy to CEO James Yamanaka, financial trajectory and capital allocation to CFO Greg Guyatt, and international growth, Germany and beyond, to Finn Age Hänsel, President, Rest of World and CSO. Organigram’s event and follow-up messages.

The company’s September 30 release framed the discussion around future growth, margins, cash generation and capital allocation, alongside an operating-footprint presentation and management Q&A. Those themes connect directly to the hub’s tests: whether Canadian operations generate cash and whether Sanity’s international growth earns an adequate return on the acquisition and integration spending. September 30 company release.

The event should no longer be treated as an upcoming catalyst. Detailed numerical claims circulating in third-party session summaries are not incorporated as new guidance here because they have not been checked against the full company replay. The prior financial guidance below retains its original August 11 date. Official event and replay page.

The sector page tracks the September 29 DEA stay, the Canadian reporting proposal and state-level developments separately from company results. Cannabis sector update and dated calendar.